Peptide compounding policy reaches White House review with BPC 157 access in play

A federal peptide compounding policy is now under review at the White House, and nobody outside government has seen its text. On October 14, HHS and the FDA sent the White House Office of Management and Budget a notice titled Interim Access Policy for Compounding Using Certain Peptides. News reports say it could let pharmacies mix some popular peptides, including BPC 157, while the formal rules are still unwritten. For patients, pharmacies and the gray market, the details will decide almost everything.

What was sent to the White House

The public record is thin. The federal regulatory dashboard lists the item under the FDA, at the notice stage, with meetings on the review booked for October 21, 23, 27 and 28. Those meetings let outside groups state their views to budget officials before anything is released. Reuters reported that the filing itself gives no details of the policy. The Associated Press, citing two people familiar with the plan, said it would let pharmacies temporarily compound some popular peptides, with BPC 157 named. HHS did not respond to requests for comment from either newsroom, and the agency has not said which peptides the notice covers, under what conditions, or from what date.

The tool reportedly at the center of the plan is enforcement discretion. That means the FDA would tell compounders it will not act against them in set cases, rather than changing the law. A Holland and Knight legal alert notes that such a step would leave covered peptides as unapproved drugs, could be narrowed or withdrawn at any time without formal rulemaking, and would likely apply only to state licensed pharmacies under Section 503A. Products sold as research chemicals, dietary supplements and large outsourcing facilities would sit outside it. The same alert says the interim access policy would not bind state boards of pharmacy or medicine, which keep their own rules on who may prescribe and mix these products.

How the peptides got here

The path started in 2023, when the FDA placed BPC 157 and more than a dozen other peptides in a category of bulk substances it said raised significant safety concerns. In April 2026 the agency said it would take 12 peptides out of that category after their nominations were withdrawn, which removed the safety label but did not make any of them legal to compound. On June 29, FDA staff reviewers advised against adding any of seven peptides to the 503A bulks list, citing poorly characterized substances, limited human data and the risk of immune reactions. On the same day the agency named a reconstituted advisory committee, and roughly half its members were reported to have ties to peptide businesses or clinics.

To put a substance on the 503A bulks list, the FDA must accept the advice, publish a proposed rule, take public comments and issue a final rule, and no law sets a deadline.

In July that committee voted to recommend six of the seven peptides: BPC 157, KPV, TB 500, MOTS c, epitalon and semax. The votes on BPC 157, KPV and TB 500 each passed 8 to 6 with one abstention, according to Holland and Knight, while emideltide, also called DSIP, failed. The recommendations are advisory only. To put a substance on the 503A bulks list, the FDA must accept the advice, publish a proposed rule, take public comments and issue a final rule, and no law sets a deadline. For scale, a 2016 proposed rule on 10 bulk substances was not finalized until 2019, which is why an interim step appeals to supporters.

Why the peptide compounding policy is contested

Supporters say the peptide compounding policy would move demand away from unregulated sellers. Health Secretary Robert F. Kennedy Jr. has argued that pharmacies must be allowed to sell peptides because people are buying gray market versions made abroad, the AP reported. Telehealth companies Hims and Hers and Noom have said they plan to offer peptides if the government eases access, and analysts cited by the AP put the market at $2 billion to $3 billion. Wellness clinic operators have framed the fight as one about medical freedom. Pharmaceutical trade groups argued in comments to the advisory committee that the FDA cannot lawfully authorize compounding through an interim policy while rulemaking is still pending.

Doctors who study drug safety point to the evidence gap. "There are a few reasons why, but one of the main ones is the absence of evidence," Dr. Caleb Alexander of the Johns Hopkins Bloomberg School of Public Health said of the earlier FDA risk listing for BPC 157, as quoted by Market Briefs. BPC 157 has shown some effects in animal and lab work, but no large human trial has tested its safety or benefit. Dr. Pieter Cohen of Harvard Medical School has warned that buying through informal channels can mean getting the wrong compound, the wrong amount, or a product contaminated with bacteria. A pharmacy label would not by itself answer questions about where the raw ingredient came from.

Gray market peptides and what pharmacies face

For now nothing has changed at the counter. No peptide in this group is on the 503A bulks list, so a pharmacy that compounds them still takes a legal risk, and the FDA has kept acting against online sellers: it sent warning letters to five online peptide vendors in August, according to Holland and Knight. Gray market peptides sold as research chemicals would not become legal under the reported plan, since that channel sits outside pharmacy compounding entirely. Our earlier coverage of Australia ending GLP 1 compounding shows how quickly a regulator can close a compounding route, and the same is true when a temporary pause on enforcement ends.

Pharmacies weighing an investment face a policy that could be revoked without notice, a likely legal challenge, and state boards that may set stricter terms. Prescribers would still be writing for unapproved drugs with thin human data, and patients would still pay cash, since insurers rarely cover unapproved compounds. A second advisory meeting on five further peptides, including GHK Cu and melanotan II, is expected before the end of February 2027, though no date is set. Readers who follow online marketing in this area can compare the pattern with the FDA warning letters sent to online GLP 1 clinics. Our rating method explains the scores below.

Conclusion

The peptide compounding policy sent to the White House on October 14 is real, but its terms are not public, and it is not an approval. If issued as reported, it would rely on enforcement discretion, cover state licensed pharmacies, and remain revocable at any time. Watch for the published text, the list of peptides it names, any conditions on sourcing and testing, and whether state boards and the courts accept it. This story is regulatory news, not medical advice.